scholarly journals HBsAg, Anti-Hepatitis C Virus and Anti-HIV Seroprevalence Among Patients Admitted to Our Hospital between 2005 and 2013

2014 ◽  
Vol 20 (3) ◽  
pp. 125-130
Author(s):  
Havva Avcıküçük ◽  
Serap Süzük ◽  
Mehmet Kavak
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Hiv Seroprevalence ◽  
Anti Hiv

scholarly journals Seroprevalence rates of transfusion-transmitted infections among blood donors in Jordan

2016 ◽  
Vol 10 (04) ◽  
pp. 377-383 ◽  
Author(s):  
Lina Souan ◽  
Faten Tout ◽  
Mahmoud Siag ◽  
Maher A. Sughayer
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Blood Donors ◽  
Hepatitis B Surface Antigen ◽  
Cancer Center ◽  
Type I ◽  
Human T Cell ◽  
Healthy Donors ◽  
Elisa Technique ◽  
Anti Hiv

Introduction: Statistics on the prevalence of donor screening for hepatitis B surface antigen (HBsAg) and anti-hepatitis C virus (anti-HCV) in Jordan are outdated. There are no studies on the prevalence of anti-HIV I/II, anti-human T-cell lymphotropic virus type I and II (anti-HTLV-I/II), or anti-syphilis. Data are also lacking on the prevalence and significance of using anti-HBc screening in Jordan. This study aimed to evaluate the prevalence of transfusion-transmissible infections (TTI) among donors at King Hussein Cancer Center and compare it with neighboring countries and to evaluate the significance of screening for anti-HB core total (anti-HBc) antibodies. Methodology: A retrospective analysis covering the period from 2009 to 2013 was conducted on records of healthy donors. The number of donors was 10,101, 12,694, 13,387, 14,256, and 12,495, respectively. Donors were screened for HBsAg, anti-HBc, anti-HIV I/II, anti-HCV, and anti-HTLV-I/II using ELISA technique, while syphilis antibodies were detected using rapid chromatographic immunoassay. Results: Among 62,933 donors, the prevalence of HBsAg was 0.52%, of anti-HBc was 6.04%, and of anti-HCV was 0.16%. None of the donors were positive for anti-HIV I/II, anti-HTLV I/II, or anti-TP. Conclusions: This study demonstrates that the seroprevalence for HBsAg, anti-HBc, and anti-HCV in Jordan was low compared to neighboring countries. None of the donors were confirmed positive for anti-HIV I/II, anti-HTLV I/II, or anti-TP during the studied period. This study demonstrates the importance of screening for anti-HBc to improve blood and platelet safety and stresses the need to complement it with an algorithm that qualifies reentry of anti-HBc false-positive donors.

scholarly journals Anti-HIV and Anti-Hepatitis C Virus Drugs Inhibit P-Glycoprotein Efflux Activity in Caco-2 Cells and Precision-Cut Rat and Human Intestinal Slices

2019 ◽  
Vol 63 (11) ◽  
Author(s):  
Ondrej Martinec ◽  
Martin Huliciak ◽  
Frantisek Staud ◽  
Filip Cecka ◽  
Ivan Vokral ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Molecular Mechanisms ◽  
Interindividual Variability ◽  
Ex Vivo ◽  
Efflux Transporter ◽  
P Glycoprotein ◽  
Bidirectional Transport ◽  
Anti Hiv ◽  
Selection Of

ABSTRACT P-glycoprotein (ABCB1), an ATP-binding-cassette efflux transporter, limits intestinal absorption of its substrates and is a common site of drug-drug interactions (DDIs). ABCB1 has been suggested to interact with many antivirals used to treat HIV and/or chronic hepatitis C virus (HCV) infections. Using bidirectional transport experiments in Caco-2 cells and a recently established ex vivo model of accumulation in precision-cut intestinal slices (PCIS) prepared from rat ileum or human jejunum, we evaluated the potential of anti-HIV and anti-HCV antivirals to inhibit intestinal ABCB1. Lopinavir, ritonavir, saquinavir, atazanavir, maraviroc, ledipasvir, and daclatasvir inhibited the efflux of a model ABCB1 substrate, rhodamine 123 (RHD123), in Caco-2 cells and rat-derived PCIS. Lopinavir, ritonavir, saquinavir, and atazanavir also significantly inhibited RHD123 efflux in human-derived PCIS, while possible interindividual variability was observed in the inhibition of intestinal ABCB1 by maraviroc, ledipasvir, and daclatasvir. Abacavir, zidovudine, tenofovir disoproxil fumarate, etravirine, and rilpivirine did not inhibit intestinal ABCB1. In conclusion, using recently established ex vivo methods for measuring drug accumulation in rat- and human-derived PCIS, we have demonstrated that some antivirals have a high potential for DDIs on intestinal ABCB1. Our data help clarify the molecular mechanisms responsible for reported increases in the bioavailability of ABCB1 substrates, including antivirals and drugs prescribed to treat comorbidity. These results could help guide the selection of combination pharmacotherapies and/or suitable dosing schemes for patients infected with HIV and/or HCV.

Hepatitis C virus infection, HIV co-infection, and associated risk among injecting drug users in Togliatti, Russia

2005 ◽  
Vol 16 (11) ◽  
pp. 749-754 ◽  
Author(s):  
Tim Rhodes ◽  
Lucy Platt ◽  
Ali Judd ◽  
Larissa Albertovna Mikhailova ◽  
Anya Sarang ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Drug Users ◽  
Injecting Drug Users ◽  
Hcv Infection ◽  
Hiv Positive ◽  
Sample Collection ◽  
Cross Sectional Survey ◽  
Almost All ◽  
Anti Hiv

The objective of this study was to estimate the prevalence of hepatitis C virus (HCV) infection and co-infection with HIV among injecting drug users (IDUs) in Togliatti City, Russia. Unlinked anonymous cross-sectional survey of IDUs recruited from community settings, with oral fluid sample collection for HCV and HIV antibody (anti-HCV, anti-HIV) testing, was carried out. The anti-HCV prevalence was 87% (357/411), anti-HIV prevalence 56% (234/418), and 93% (214/230) of HIV-positive IDUs were co-infected with HCV. Only 23% (94/411) of those HCV positive self-reported as such. In an adjusted model, increased odds of HCV positivity were associated with needle and syringe, as well as injecting paraphernalia sharing in the last four weeks. IDUs injecting more than once with the same needle also had raised odds. There were no marked associations between HCV positivity and the duration of injecting or age group. Almost all IDUs were HCV positive, and almost all HIV-positive IDUs were HCV co-infected. There is an urgent need to maximize syringe distribution coverage, develop health promotion targeting HCV prevention for IDUs, and improve access among IDUs to treatments for HIV and HCV infection.

scholarly journals Serosurvey of anti-treponema pallidum (syphilis), anti-hepatitis C virus and anti-HIV antibodies in homeless persons of São Paulo city, southeastern Brazil

2021 ◽  
pp. 101602
Author(s):  
Laís Giuliani Felipetto ◽  
Pedro Irineu Teider-Junior ◽  
Felipe Fortino Verdan da Silva ◽  
Anahi Chechia do Couto ◽  
Louise Bach Kmetiuk ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Treponema Pallidum ◽  
Homeless Persons ◽  
Sao Paulo ◽  
Southeastern Brazil ◽  
São Paulo ◽  
Hiv Antibodies ◽  
Anti Hiv

Antibody to hepatitis C virus in blood donors found positive for other agents. II. Anti-HIV-1

1991 ◽  
Vol 1 (3) ◽  
pp. 195-197
Author(s):  
M. C. Moore ◽  
J. A. J. Barbara ◽  
P. E. Hewitt
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Blood Donors ◽  
Anti Hiv ◽  
Hiv 1

scholarly journals Proteome‐Wide Anti–Hepatitis C Virus (HCV) and Anti‐HIV Antibody Profiling for Predicting and Monitoring the Response to HCV Therapy in HIV‐Coinfected Patients

2010 ◽  
Vol 202 (6) ◽  
pp. 894-898 ◽  
Author(s):  
Peter D. Burbelo ◽  
Joseph A. Kovacs ◽  
Kathryn H. Ching ◽  
Alexandra T. Issa ◽  
Michael J. Iadarola ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Hcv Therapy ◽  
Antibody Profiling ◽  
Anti Hiv

Human Immunodeficiency Virus and Hepatitis C Virus Infections among Patients Attending Sexually Transmitted Disease Clinics, Regional 2, Thai land

2000 ◽  
Vol 12 (1) ◽  
pp. 41-45 ◽  
Author(s):  
Pipat Luksamijarulkul ◽  
Porntip Khemnak ◽  
Oranut Pacheun
Keyword(s):  
Human Immunodeficiency Virus ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Condom Use ◽  
Sexually Transmitted Disease ◽  
Transmitted Disease ◽  
Sexual Contact ◽  
Sexually Transmitted ◽  
Immunodeficiency Virus ◽  
Anti Hiv

A cross-sectional study of 400 patients attending sexually transmitted disease (STD) clinics at The Venereal Diseases and AIDS Centers, Regional 2, Thailand, was conducted from January to December 1996 in order to investigate the antibody prevalence to human immunodeficiency virus (HIV) and hepatitis C virus (HCV) and to describe some epidemiological characteristics among HIV and HCV co-infected individuals. The studied patients were interviewed and their blood specimens were collected for determining anti-HIV and anti-HCV antibodies. The results revealed that the prevalence of anti-HIV among studied patients was 25%, while 7.5% were positive for anti-HCV The positivity of both antibodies present in the same individuals was 3.3% (13/400 cases). The highest prevalences of anti-HIV, anti-HCV and both antibodies were found in studied patients aged 20 years or less. Patients with primary education, or lower, had relatively higher prevalence of anti-HIV and/ or anti-HCV than those with higher level education. A relatively higher prevalence was found among commercial sex workers and labourers. Among 13 HIV and HCV co-infected individuals, there were four cases who had histories of sexual contact without condom use, but no history of parenteral contact. The rest (9/13) had histories of both parenteral contact and sexual contact without condom use. Asia Pac J Public Health 2000;12(1):41-45

scholarly journals Interleukin-27, an Anti-HIV-1 Cytokine, Inhibits Replication of Hepatitis C Virus

2010 ◽  
Vol 30 (6) ◽  
pp. 427-431 ◽  
Author(s):  
Astrid C. Frank ◽  
Xiaozhen Zhang ◽  
Antonios Katsounas ◽  
Jennifer P. Bharucha ◽  
Shyamasundaran Kottilil ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Interleukin 27 ◽  
Anti Hiv ◽  
Hiv 1
Sign in / Sign up

Export Citation Format

Share Document